文献速递系统性红斑狼疮

达匹利珠单抗聚乙二醇结合物治疗中重度活动性系统性红斑狼疮的2期随机安慰剂对照试验

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该2期随机安慰剂对照试验评估达匹利珠单抗聚乙二醇结合物(DZP)治疗中重度活动性SLE的剂量反应、疗效与安全性;主要终点第24周BICLA应答率未拟合预设剂量反应模型(最佳拟合Emax模型P=0.07),但各DZP组临床与免疫学指标较安慰剂改善,且耐受性良好。

要点

  • 主要终点未达标:第24周BICLA应答率未拟合预设剂量反应模型(Emax模型P=0.07)。
  • 各DZP组第24周临床与免疫学结局较安慰剂改善,严重治疗出现不良事件发生率低且与安慰剂相似。
  • 停用DZP后SLEDAI-2K、PGA、BILAG、CLASI稳定,BICLA与SRI-4应答率下降,BILAG flare增加。

核心结论

  • 尽管主要目标未达成,DZP耐受性良好,第24周多个临床与免疫学疾病活动度指标较安慰剂改善。
  • DZP的潜在临床获益值得进一步研究。

研究设计与样本

  • 2期随机安慰剂对照试验,纳入中重度活动性SLE成人患者(SLEDAI-2K≥6且≥1个BILAG A或≥2个BILAG B域评分)。
  • 患者需接受稳定剂量CS(≤40 mg/天泼尼松等效)、抗疟药或免疫抑制剂;允许稳定LN(蛋白尿≤2 g/天)且未用高剂量CS或CYC者入组。
  • 随机接受安慰剂或静脉DZP(6/24/45 mg/kg)联合标准治疗,每4周至第24周,此后仅标准治疗至第48周。

主要发现

  • 所有DZP组第24周临床与免疫学结局较安慰剂改善。
  • BICLA应答率未拟合预设剂量反应模型,最佳拟合模型(Emax)P=0.07。
  • 各DZP组严重治疗出现不良事件发生率低且与安慰剂相似。
  • 停用DZP后SLEDAI-2K、PGA、BILAG、CLASI评分稳定,BICLA与SRI-4应答率下降,BILAG flare增加,免疫学参数向基线回归。

关键数值与推荐

  • 主要目标为基于第24周BICLA应答率建立剂量反应关系。
  • 入组标准:SLEDAI-2K≥6且≥1个BILAG A或≥2个BILAG B域评分;稳定CS≤40 mg/天泼尼松等效。
  • 稳定LN允许入组条件:蛋白尿≤2 g/天且未接受高剂量CS或CYC。

临床怎么用

  • DZP联合标准治疗在中重度活动性SLE中耐受性良好,第24周多指标改善,但主要剂量反应终点未达标。
  • 停药后疾病活动度指标稳定但应答率下降、flare增加,提示需关注停药策略。

局限性

  • 主要终点未达成,预设剂量反应模型未获支持(Emax模型P=0.07)。
  • 停药后BICLA与SRI-4应答率下降可能与使用禁用补救药物有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the dose-response, efficacy and safety of dapirolizumab pegol (DZP) in patients with SLE. METHODS: Adults with moderately to severely active SLE (SLEDAI-2K score ≥6 and ≥1 BILAG A or ≥2 BILAG B domain scores), receiving stable CS (≤40 mg/day prednisone-equivalent), antimalarial or immunosuppressant drugs were included. Patients with stable LN (proteinuria ≤2 g/day) not receiving high-dose CS or CYC were permitted entry. Randomized patients received placebo or i.v. DZP (6/24/45 mg/kg) and standard-of-care (SOC) treatment every 4 weeks to week 24, after which patients received only SOC to week 48. The primary objective was to establish a dose-response relationship based on week 24 BILAG-Based Composite Lupus Assessment (BICLA) responder rates. RESULTS: All DZP groups exhibited improvements in clinical and immunological outcomes vs placebo at week 24; however, BICLA responder rates did not fit pre-specified dose-response models [best-fitting model (Emax): P = 0.07]. Incidences of serious treatment-emergent adverse events across DZP groups were low and similar to placebo. Following DZP withdrawal, SLEDAI-2K, physician's global assessment (PGA), BILAG, and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores stabilized; BICLA and SLE Responder Index (SRI-4) responder rates declined (likely due to interventions with disallowed escape medications), BILAG flares increased, and immunologic parameters returned towards baseline. CONCLUSIONS: Although the primary objective was not met, DZP appeared to be well tolerated, and patients exhibited improvements across multiple clinical and immunological measures of disease activity after 24 weeks relative to placebo. The potential clinical benefit of DZP warrants further investigation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Furie RA, Bruce IN, Dörner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33956056. doi:10.1093/rheumatology/keab381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。